Eric Bjerkholt - 11 Aug 2026 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Reporting relationship: CHIEF FINANCIAL OFFICER
Issuer ticker: MIRM
Reported as of: 11 Aug 2026
Net transaction value: -$599,510
SEC form: 4
Accepted by SEC: 12 Aug 2026, 17:14:43 UTC
Prior SEC filing: 08 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Judit Ryvkin, Attorney-in-Fact

Key filing fact

Eric Bjerkholt filed Form 4 for Mirum Pharmaceuticals, Inc. (MIRM) on 12 Aug 2026.

Key facts

This page summarizes Eric Bjerkholt's Form 4 filing for Mirum Pharmaceuticals, Inc. (MIRM).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 12 Aug 2026, 17:14.

Change

Previous filing in this sequence was filed on 08 Jul 2026.
Current net transaction value: -$599,510.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001197350 Primary reporting owner

BJERKHOLT ERIC

Relationship: CHIEF FINANCIAL OFFICER
Address: C/O MIRUM PHARMACEUTICALS, INC., 989 E HILLSDALE BLVD., SUITE 300, FOSTER CITY
Signature: /s/ Judit Ryvkin, Attorney-in-Fact
Signature date: 12 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MIRM transaction

Common Stock

Sale

Transaction value: $599,510
Shares: -6,001
Change %: -14%
Price: $99.90
Shares after: 36,355
Date: 11 Aug 2026
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 9, 2026.

Footnote F2

. The weighted average sale price for the transaction reported was $99.901633, and the range of prices were between $99.90 and $99.93. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Footnote F3

Includes 175 shares of common stock that were acquired by the Reporting Person on May 10, 2026, pursuant to the Issuer's Employee Stock Purchase Plan.